September 20, 2017
EC approves Novartis’s cancer drug for 2 indications
The European Commission has approved Novartis’s Rydapt for two indications in rare cancers, in combination with standard daunorubicin and cytarabine…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Rydapt